BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen R, Li Q, Xu S, Ye C, Tian T, Jiang Q, Shan J, Ruan J. Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. Cancer Cell Int 2022;22:73. [PMID: 35148789 DOI: 10.1186/s12935-021-02435-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-01168-8] [Reference Citation Analysis]
2 Sun H, Xing C, Jiang S, Yu K, Dai S, Kong H, Jin Y, Shan Y, Yang W, Wang Z, Xiao J, Wang H, Wang W, Li Z, Shi K. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report. Front Immunol 2022;13:963031. [DOI: 10.3389/fimmu.2022.963031] [Reference Citation Analysis]
3 Zhu Y, Qin LX. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00189-8. [PMID: 35977874 DOI: 10.1016/j.hbpd.2022.08.003] [Reference Citation Analysis]
4 Sukowati C, Cabral LKD, Tiribelli C. Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle. Ann Hepatol 2022;27:100740. [PMID: 35809835 DOI: 10.1016/j.aohep.2022.100740] [Reference Citation Analysis]